Skip to main content
Article thumbnail
Location of Repository

Consensus of German Transplant Centers on Hematopoietic Stem Cell Transplantation in Fanconi Anemia

By M. M. Chao, W. Ebell, P. Bader, R. Beier, B. Burkhardt, T. Feuchtinger, R. Handgretinger, H. Hanenberg, U. Koehl, C. Kratz, B. Kremens, P. Lang, R. Meisel, I. Mueller, C. Roessig, M. Sauer, P. G. Schlegel, A. Schulz, B. Strahm, F. Thol and K. W. Sykora

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is currently the only curative therapy for the severe hematopoietic complications associated with Fanconi anemia (FA). In Germany, it is estimated that 10–15 transplants are performed annually for FA. However, because FA is a DNA repair disorder, standard conditioning regimens confer a high risk of excessive regimen-related toxicities and mortality, and reduced intensity regimens are linked with graft failure in some FA patients. Moreover, development of graft-versus-host disease is a major contributing factor for secondary solid tumors. The relative rarity of the disorder limits HSCT experience at any single center. Consensus meetings were convened to develop a national approach for HSCT in FA. This manuscript outlines current experience and knowledge about HSCT in FA and, based on this analysis, general recommendations reached at these meetings

Topics: fanconi anemia, stem cell transplantation
Publisher: Thieme
Year: 2015
DOI identifier: 10.1055/s-0035-1548841
OAI identifier: oai:scholarworks.iupui.edu:1805/6606
Provided by: IUPUIScholarWorks

Suggested articles


To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.